• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ: BMEA )

4.230 +0.150 (+3.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biomea Fusion, Inc. - Common Stock

< Previous 1 2 3 Next >
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
December 17, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
December 16, 2024
Tuesday, December 17, 2024 at 8:00 am EST 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 12, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
December 09, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
December 06, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
November 18, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
October 30, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
October 29, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
October 21, 2024
Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
October 15, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
October 07, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
October 01, 2024
International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s... 
From Biomea Fusion, Inc.
Via GlobeNewswire
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
September 26, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 01, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
July 31, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
July 08, 2024
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
July 03, 2024
From The Rosen Law Firm PA
Via GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
June 16, 2024
From The Rosen Law Firm PA
Via GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
From FN Media Group LLC
Via GlobeNewswire
Biomea Fusion, Inc. (BMEA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 14, 2024
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Rosen Law Firm Encourages Biomea Fusion, Inc. Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – BMEA
June 13, 2024
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
June 06, 2024
From Schall Law
Via GlobeNewswire
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
June 06, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
June 03, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
May 30, 2024
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
May 02, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 01, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap